Molecular therapy in pancreatic adenocarcinoma

Lancet Oncology

Volumn 5, Issue 9, 2004, Pages 541-549

  MacKenzie, Mary J ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CILENGITIDE; CISPLATIN; COMPLEMENTARY RNA; DOCETAXEL; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GANCICLOVIR; GEMCITABINE; IMMUNOTOXIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; IRINOTECAN; ISIS 2503; METRONIDAZOLE; MONOCLONAL ANTIBODY; ONYX 015; OXALIPLATIN; PROTEIN P53; PROTEIN P73; SMAD3 PROTEIN; THALIDOMIDE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HYPERTENSION; IMMUNOMODULATION; MULTIMODALITY CANCER THERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT PLANNING; VIRAL GENE DELIVERY SYSTEM;

EID: 4444366400     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01565-7     Document Type: Review

References (77)

1. Jemal A Thomas A Murray T et al. Cancer Statistics CA Cancer J Clin 52 2002 23-47
2. Burris HA Moore MJ Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial J Clin Oncol 15 1997 2403-2413
3. Berlin JD Catalano P Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270-3275
4. Haller DG. New perspectives in the management of pancreas cancer Semin Oncol 4 2003 3-10
5. Tsai JY Iannitti DA Safran H. Combined modality therapy for pancreatic cancer Semin Oncol 30 2003 71-79
6. Hilgers W Kern SE. Molecular genetic basis of pancreatic adenocarcinoma Genes Chrom Canc 26 1999 1-12
7. Kelley JR Fraser MM Hubbard JM et al. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer Anticancer Res 23 2003 2007-2013
8. Sohn TA Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: a review Surg Oncol 9 2000 95-101
9. Ramirez PJ Vickers SM. Current status of gene therapy for pancreatic cancer Curr Surg 61 2004 84-92
10. Tseng JF Mulligan RC. Gene therapy for pancreatic cancer Surg Oncol Clin N Am 11 2002 537-569
11. Perez R.P. Smith J.W. Alberts S.R. et al. Phase II trial of ISIS 2503, an antisense inhibitor of H-ras, in patients with advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2001; abstr 628.
12. Burch P.A. Alberts S.R Schroeder M.T. et al. Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) phase II trial. Proc Am Soc Clin Oncol 2003; abstr 1038.
13. Bouvet M Bold RJ Lee J et al. Adenovirus-mediated wild-type p53 tumour suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer Ann Surg Oncol 5 1998 681-688
14. Hwang RF Gordon EM Anderson WF et al. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene Surgery 124 1998 143-151
15. Rodlicker F Putzer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement Cancer Res 63 2003 2737-2741
16. Duda DG Sunamura M Lefter LP et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells Oncogene 22 2003 6857-6864
17. Wang J Lu XX Chen D-Z et al. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer World J Gastroenterol 10 2004 400-403
18. Makinen K Loimas S Wahlfors J et al. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer J Gene Med 2 2000 361-367
19. Greco E Fogar P Basso D et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumour effect Pancreas 25 2002 21-29
20. Fogar P Greco E Basso D et al. Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model Eur J Surg Oncol 29 2003 721-730
21. Alvarez RD Gomez-Navarro J Wang M et al. Adenoviral-mediated suicide gene therapy for ovarian cancer Mol Ther 2 2000 524-530
22. Klatzmann D Cherin P Bensimon G et al. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma Hum Gene Ther 9 1998 2585-2594
23. Kirn DH. Replication-selective microbiological agents: fighting cancer with targeted germ warfare J Clin Invest 105 2000 837-839
24. Hecht JR Bedford R Abbruzzese JL et al. A phase I/II trial of intratumoural endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma Clin Can Res 9 2003 555-561
25. Schulze-Berkamen H Krammer P. Apoptosis in cancer- implication for therapy Semin Oncol 31 2004 90-119
26. Katz MH Spivak DE Takimoto S et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumour necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter Ann Surg Oncol 10 2003 762-772
27. Peplinski GR Tsung K Meko JB et al. In vivo gene therapy of a murine pancreas tumour with recombinant vaccinia virus encoding human interleukin-1 beta Surgery 118 1995 185-190
28. APutzer BM Rodlicker F Hitt MM et al. Improved treatment of pancreatic cancer by IL-2 and B7.1 costimulation: antitumour efficacy and immunoregulation in a nonimmunogenic tumor model Mol Ther 5 2002 405-412
29. Kawakami K Kawakami M Husain SR et al. Potent antitumour activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo Gene Ther 10 2003 1116-1128
30. Nakamura T Furukawa Y Nakagawa H et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and notral ductal epithelial cells selected for purity by laser microdissection Oncogene 23 2004 2385-2400
31. Hughes RM. Strategies for cancer gene therapy J Surg Oncol 85 2004 28-37
32. Douglas JT. Cancer gene therapy Technol Cancer Res Treat 2 2003 51-64
33. Folkman J. Role of angiogenesis in tumour growth and metastasis Semin Oncol 29 6 suppl 16 2002 15-18
34. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer Mol Cancer 2 2003 1-8
35. Bruns CJ Shrader M Harbison MT et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice Int J Cancer 102 2002 101-108
36. Hurwitz H. Fehrenbacher L. Cartwright T. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003; abstr 3646.
37. Yang JC Haworth L Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427-434
38. Kindler H.L. Friberg G. Stadler W.M. et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic carcinoma: interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium. Proc 2004 Gastrointestinal Cancers Symposium; abstr 86.
39. von Moos R Stolz R Cerny T et al. Thalidomide: from tragedy to promise Swiss Med Wkly 133 2004 77-87
40. Arora A. Lynch J. Brand R. et al. Phase I trial of docetaxel plus thalidomide in patients with progressive pancreatic adenocarcinoma after gemcitabine-based therapy. Proc 2004 Gastrointestinal Cancers Symposium; abstr 142.
41. Berger AC Alexander HR Tang G et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumour angiogenesis Microvasc Res 60 2000 70-80
42. Schwarz R.E. Konduri S. Schwarz M.A. In vivo monotherapy and combination treatment of pancreatic cancer with the antiendothelial agent EMAP-II. Proc 2004 Gastrointestinal Cancers Symposium; abstr 146.
43. Stopeck A Sheldon M Vahedian M et al. Results of a phase I dose-escalating study of the antiangiogenic agent SU5416, in patients with advanced malignancies Clin Cancer Res 8 2002 2798-2805
44. Bhargava P Marshall JL Rizvi N et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer Clin Cancer Res 5 1999 1989-1995
45. Eskens FA Dumez H Hoekstra R et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours Eur J Cancer 39 2003 917-926
46. Fisher WE Berger DH. Angiogenesis and antiangiogenic strategies in pancreatic cancer Int J Gastrointest Cancer 33 2003 7-88
47. Chau I Rigg A Cunningham D. Matrix metalloproteinase inhibitors-an emphasis on gastrointestinal malignancies Crit Rev Oncol/Hematol 45 2003 151-176
48. Bramhall DR Schulz J Nemunitis J et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161-167
49. Moore MJ Hamm J Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY-12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296-3302
50. Alves F. Borchers U. Laube S. et al. The selective matrix metalloproteinase inhibitor Ro28-2653, reduces tumour progression in combination with the cytostatic drug gemcitabine I an orthotopic pancreatic tumour model. Proc Am Assoc Cancer Res 2003; abstr 4626.
51. Coley WB. A report of recent cases of inoperable sarcomas successfully treated with mixed toxins of erysipelas and Bacillus prodigiosus Surg Gynecol Obstet 13 1911 174-190
52. Kaufman HL Di Vito J Horig H. Immunotherapy for pancreatic cancer: current concepts Hematol Oncol Clin North Am 16 2002 159-197
53. Laheru DA Jaffee EM. Potential role of tumour vaccines in GI malignancies Oncology 14 2000 1-22
54. Pecher G Haring A Kaiser L et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial Cancer Immunol Immunother 51 2002 669-673
55. Morse MA Nair SK Boczkowski D et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer Int J Gastrointest Cancer 32 2002 1-6
56. Gjertsen MK Buanes T Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:clinical and immunological responses in patients with pancreatic adenocarcinoma Int J Cancer 92 2001 441-450
57. Jaffee EM Hruban RH Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 19 2001 145-156
58. Argani P Rosty C Reiter RE et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma Cancer Res 61 2001 4320-4324
59. Sarela A Verbeke CS Ramsdale J et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma Br J Cancer 86 2002 886-892
60. Hassan R. Laszik Z. Lerner M.R et al. Mesothelin, a cell surface glycoprotein, as a target for tumor specific therapy of pancreatic cancer. Proc Am Soc Clin Oncol 2003; abstr 1138.
61. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy Semin Oncol 30 3 suppl 7 2003 3-14
62. Lemoine NR Highes CM Barton CM et al. The epidermal growth factor receptor in human pancreatic cancer J Pathol 166 1992 7-12
63. Xiong HQ Abbruzzese J. Epidermal growth factor receptor-targeted therapy for pancreatic cancer Semin Oncol 29 suppl 14 2002 31-37
64. Abbruzzese J.L. Rosenburg A. Xiong Q. et al. Phase II study of anti-epidermal growth factor receptor antibody cetuximab (IMC-225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; abstr 518.
65. Bruns CJ Solorzano CC Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 60 2000 2926-2936
66. Dragovich T. Patnaik A. Rowinsky E.K. et al. A phase IB trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. Proc Am Soc Clin Oncol 2003; abstr 895.
67. Morgan J.A. Bukowski R.M. Xiong H. et al. Preliminary report of a phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2003; abstr 788.
68. Sridhar SS Seymour L Shepherd FA. Inhibitors of epidermal growth factor receptors: a review of clinical research with a focus on non-small-cell lung cancer Lancet Oncol 4 2003 396-406
69. Wolff RA. Exploiting molecular targets in pancreatic cancer Hematol Oncol Clin North Am 16 2002 139-157
70. Gibbs J.F. Sreekuma B. Hylander B. et al. Low incidence of EGFR and Her2/neu positivity in pancreatic cancer. Proc 2004 Gastrointestinal Cancers Symposium; abstr 134.
71. Safran H. Ramanathan R.K. Schwartz J. et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress her2/neu. Proc Am Soc Clin Oncol 2001; abstr 517.
72. Waterhouse D.M. Rinehart J. Adjei A.A. et al. A phase 2 study of an oral MEK inhibitor CI-1040 in patients with advanced non-small cell, breast, colon or pancreatic cancer. Proc Am Soc Clin Oncol 2003; abstr 816.
73. Johnston SRD. Farnesyl transferase inhibitors: a novel targeted therapy for cancer Lancet Oncol 2 2001 18-26
74. Cohen SJ Ho L Ranganathan S et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma J Clin Oncol 21 2003 1301-1306
75. Van Cutsem E. Karasek P. Oettle H. et al. Phase III trial comparing gemcitabine+R115777 (Zarnestra) versus gemcitabine+placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2002; abstr 517.
76. Ito H Gardner-Thorpe J Zinner MJ et al. Inhibition of tyrosine kinase SRC suppresses pancreatic cancer invasiveness Surgery 134 2003 221-226
77. Yezhelev M. Wagner C. Kohl G. et al. In vivo and in vitro effects of a novel Src tyrosine kinase inhibitor on human pancreatic cancer in a nude mouse model. Proc Am Assoc Cancer Res 2003; abstr 1718.